Boehringer Ingelheim

CureVac secured Gates Foundation backing

CureVac to build plant with Gates Foundation money

By Gareth Macdonald

CureVac will build a manufacturing facility for mRNA vaccines after a $52m (€46m)  Gates Foundation investment that also brings an IPO one step closer according to majority shareholder Dietmar Hopp.

Boehringer Ingelheim licenses CureVac mRNA vaccine for up to $600m

Boehringer Ingelheim licenses CureVac mRNA vaccine for up to $600m

By Zachary Brennan

Boehringer Ingelheim will pay mRNA drug developer CureVac up to €465m ($600m) for an exclusive global license and development collaboration on CureVac’s potential mRNA vaccine in early clinical development for the treatment of lung cancer. 

Spotlight

Follow us

Products

View more

Featured Suppliers

All